Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study

Background. Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Methods. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days. Primary outcomes included adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Marty, Francisco M., Man, Choy Y., van der Horst, Charles, Francois, Bruno, Garot, Denis, Máňez, Rafael, Thamlikitkul, Visanu, Lorente, José A., Álvarez-Lerma, Francisco, Brealey, David, Zhao, Henry H., Weller, Steve, Yates, Phillip J., Peppercorn, Amanda F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047294/
https://www.ncbi.nlm.nih.gov/pubmed/23983212
http://dx.doi.org/10.1093/infdis/jit467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047294/
https://www.ncbi.nlm.nih.gov/pubmed/23983212
http://dx.doi.org/10.1093/infdis/jit467

Ejemplares similares